Axovant Sciences Falls 70% After Phase 3 Intepirdine MINDSET Trial Doesn't Meet Endpoint

Axovant Sciences Ltd AXON shares are trading lower by $17.65, or 72 percent, at $6.60 in Tuesday's session.

The catalyst for the sharp decline is the announcement that is Phase 3 Intepirdine MINDSET clinical trial did not meet its co-primary efficacy endpoints. The drug is being tested for use with patients with Alzheimer's disease.

After a much lower open, Axovant attempted to rally but found sellers at $7.40 and resumed its move lower. It went on to breach its opening print of $6.37, but only fell to $6.13 and is attempting to rebound.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!